Aim: To evaluate and correlate the epidermal growth factor receptor (EGFR) expression in oral squamous cell carcinomas (OSCC) patients with metastasis and without metastasis. Materials and methods: The study comprised of 40 samples, 20 cases of metastatic and 20 nonmetastatic OSCC. All the cases were immunostained for EGFR antibody. Epidermal growth factor receptor stained sections were evaluated for staining intensity and distribution. The differences between the groups were statistically analyzed using Chi-square test. Results: Immunoexpression of EGFR in OSCC was 100% among the study groups, where metastatic group showed an increased positive expression comparing to nonmetastatic OSCC that show statistically significance among the study groups. Conclusion: Expression of EGFR can be used as reliable biomarker for prognosis which can be employed in the prediction of the survival of the patient with OSCC. Clinical significance: Since we are in the theragnostic era, evaluating and quantifying the expression of EGFR in OSCC patient will definitely pave a way in targeted drug therapy and personalized medicine for the diseased.